To address these challenges, future studies could explore combinatorial strategies such as co-administration of immune checkpoint inhibitors to reverse T-cell exhaustion, optimization of dose regimens to reduce the effects of continuous antigen exposure, and the use of protease inhibitors to prevent shedding of BAFFR, BCMA, and TACI, thereby enhancing receptor expression on the tumor cell surface. Here, TNFRSF13B is linked to neoplasm.